BARICITINIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L04AA37
UNII: ISP4442I3Y

Structure
InChI Key XUZMWHLSFXCVMG-UHFFFAOYSA-N
Smile CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
InChI
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H17N7O2S
Molecular Weight 371.43
AlogP 1.1
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 5.0
Polar Surface Area 120.56
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 26.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tyrosine-protein kinase JAK1 inhibitor PubMed
Primary Target
Janus kinase 1
Janus kinase 2
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakA family
- 0-290 - - 94
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakB family
- 0-290 - - 94

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 4 D001172 FDA
Uveitis 3 D014605 ClinicalTrials
Lupus Erythematosus, Systemic 3 D008180 ClinicalTrials
Dermatitis, Atopic 3 D003876 ClinicalTrials
Arthritis, Juvenile 3 D001171 ClinicalTrials
Alopecia Areata 3 D000506 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Dermatomyositis 3 D003882 ClinicalTrials
Giant Cell Arteritis 2 D013700 ClinicalTrials
Liver Cirrhosis, Biliary 2 D008105 ClinicalTrials
Myositis 2 D009220 ClinicalTrials
Pneumonia 2 D011014 ClinicalTrials
Vitiligo 2 D014820 ClinicalTrials
Diabetes Mellitus, Type 1 2 D003922 ClinicalTrials
Diabetic Nephropathies 2 D003928 ClinicalTrials
Psoriasis 2 D011565 ClinicalTrials
Graft vs Host Disease 1 D006086 ClinicalTrials
Sjogren's Syndrome 1 D012859 ClinicalTrials
Dermatitis, Allergic Contact 0 D017449 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
12.58
Respiratory, thoracic and mediastinal disorders
9.75
Vascular disorders
9.07
Gastrointestinal disorders
8.39
General disorders and administration site conditions
7.9
Nervous system disorders
7.83
Skin and subcutaneous tissue disorders
5.31
Musculoskeletal and connective tissue disorders
4.94
Cardiac disorders
4.81
Injury, poisoning and procedural complications
4.38
Immune system disorders
3.95
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.76
Investigations
3.27
Blood and lymphatic system disorders
3.02
Renal and urinary disorders
2.34
Hepatobiliary disorders
2.16

Cross References

Resources Reference
CAS NUMBER 1187594-09-7
ChEBI 95341
ChEMBL CHEMBL2105759
DrugBank DB11817
DrugCentral 5202
EPA CompTox DTXSID30152228
FDA SRS ISP4442I3Y
Guide to Pharmacology 7792
PDB 3JW
PubChem 44205240
SureChEMBL SCHEMBL871150
ZINC ZINC000073069247
CONTENTS